ICER Estimate Of Remdesivir’s Value Kicks Off Pandemic Drug Price Debate

By John Wilkerson, Ariel Cohen / May 4, 2020 at 11:38 AM
Updated Story Remdesivir is worth up to $4,500 for each patient, according to the Institute for Clinical and Economic Review, and that initial estimate kicks off the debate over pandemic drug prices. This also could be the week that CMS announces a plan to lower insulin costs for seniors. Plus, hospitals expect the agency to propose a rule that could include reimbursement policy for expensive CAR-T cancer drugs. Gilead’s remdesivir is the first drug to show real...


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.